Sumitomo Pharma Earnings Likely to Be Driven by Key Drugs — Market Talk

Sumitomo Pharma's earnings are likely to be driven by strong sales of prostate cancer drug Orgovyx and overactive bladder drug Gemtesa, Jefferies analysts say in a note. The U.S. bank raises its estimates for Sumitomo Pharma's revenue and core operating profit in the coming years, citing sales grow…